ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 466.2 | 455.9 | 430.9 |
| Other income | 2.2 | -0.0 | 1.6 |
| Total income | 469.7 | 475.6 | 441.3 |
| Profit before exceptional items & tax | -19.6 | -28.7 | -36.7 |
| Exceptional items | 97.3 | 3.7 | 0.0 |
| Profit before tax | 77.7 | -25.0 | -36.7 |
| Net profit | 65.4 | -23.7 | -36.4 |
| Operating margin | 16.5% | -5.3% | -8.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +8.20% |
|---|---|
| Operating profit, year on year | +266.30% |
| Operating profit, quarter on quarter | +366.70% |
NSE results filing, NSE: INDOCO. Figures extracted from the filing.
Indoco Remedies Ltd: key numbers
- Share price
- ₹219.51
- Market cap
- ₹2,026 Cr
- Revenue (annual)
- ₹1,845 Cr
- Net profit (annual)
- ₹-95.14 Cr
- P/E (TTM)
- 63.5×Sector 43.8×
- Promoter holding
- 58.92%+0.06% QoQ
- FII holding
- 1.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indoco Remedies Ltd
All →Indoco Remedies Promoter Buying: ₹0.45 Cr
Four Indoco Remedies promoters bought 20,740 shares on NSE on 5 November 2026. Aggregate purchase value is about Rs.0.45 Crore.
- Value
- ₹0.45 Cr
Indoco Remedies Promoter Buying: ₹0.03 Cr
Indoco Remedies promoter and director Suresh G Kare bought 1,335 equity shares on the open market on 6 November 2026, raising holding from 1.42% to 1.42%. The trade value is Rs.2,84,248, about Rs.0.03 Crore.
- Value
- ₹0.03 Cr
Indoco Remedies Promoter Buying: ₹0.13 Cr
Indoco Remedies promoters Aditi M. Panandikar and Madhura Suresh Kare acquired a combined 5,996 equity shares via market purchase. The total transaction value is ₹0.13 Crore.
- Value
- ₹0.13 Cr
- Promoter stake change
- +0.01%
Indoco Remedies Promoter Buying: ₹0.17 Cr
Indoco Remedies' promoters Aditi Panandikar and Madhura Suresh Kare acquired 8,004 shares via market purchase. The total transaction value is ₹0.17 Crore.
- Value
- ₹0.17 Cr
Indoco Remedies Earnings Call Transcript: Key Takeaways
Indoco Remedies hit record quarterly revenue exceeding ₹500 Cr, but faced margin compression from elevated geopolitical freight and material costs.
- Call
- Guides 10% growth
Indoco Remedies Business Update
Indoco's CRO AnaCipher received ANVISA Brazil approval for clinical and bioanalytical facilities. This expands its regulatory footprint to conduct bioequivalence studies in Brazil and Latin America.